



(86) Date de dépôt PCT/PCT Filing Date: 2007/01/18  
(87) Date publication PCT/PCT Publication Date: 2007/08/23  
(85) Entrée phase nationale/National Entry: 2008/08/12  
(86) N° demande PCT/PCT Application No.: EP 2007/000430  
(87) N° publication PCT/PCT Publication No.: 2007/093264  
(30) Priorité/Priority: 2006/02/14 (DE10 2006 006 648.0)

(51) Cl.Int./Int.Cl. *C07C 243/38* (2006.01),  
*A61K 31/15* (2006.01), *A61P 3/00* (2006.01)


(71) Demandeur/Applicant:  
MERCK PATENT GESELLSCHAFT MIT  
BESCHRAENKTER HAFTUNG, DE

(72) Inventeurs/Inventors:  
GERICKE, ROLF, DE;  
KLEIN, MARKUS, DE;  
MEDERSKI, WERNER, DE;  
BEIER, NORBERT, DE;  
LANG, FLORIAN, DE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : HYDRAZIDES D'ACIDE MANDELIQUE

(54) Title: MANDELIC HYDRAZIDES



(57) Abrégé/Abstract:

New mandelic hydrazides of the formula (I) in which R<sup>1</sup> - R<sup>11</sup> are as defined in claim (1) are SGK inhibitors and can be used to treat SGK-associated illnesses and afflictions such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertension, cardiovascular diseases and renal diseases, generally in connection with any kind of fibroses and inflammatory processes.



## Abstract

New mandelic hydrazides of the formula (I) in which  $R^1 - R^{11}$  are as defined in claim (1) are SGK inhibitors and can be used to treat SGK-associated illnesses and afflictions such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertension, cardiovascular diseases and renal diseases, generally in connection with any kind of fibroses and inflammatory processes.

## Mandelic hydrazides

### BACKGROUND OF THE INVENTION

5

The invention was based on the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments.

10

The present invention relates to compounds in which the inhibition, regulation and/or modulation of signal transduction of kinases, in particular cell volume-regulated human kinase h-sgk (human serum and glucocorticoid dependent kinase or SGK), plays a role, furthermore to pharmaceutical compositions which comprise these compounds, and to the use of the compounds for the treatment of SGK-induced diseases.

15

20

The SGKs with the isoforms SGK-1, SGK-2 and SGK-3 are a serine/threonine protein kinase family (WO 02/17893).

The compounds according to the invention are preferably selective inhibitors of SGK-1. They may furthermore be inhibitors of SGK-2 and/or SGK-3.

25

30

35

In detail, the present invention thus relates to compounds which inhibit, regulate and/or modulate SGK signal transduction, to compositions which comprise these compounds, and to processes for the use thereof for the treatment of SGK-induced diseases and complaints, such as diabetes (for example diabetes mellitus, diabetic nephropathy, diabetic neuropathy, diabetic angiopathy and microangiopathy), obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases (for example cardiac fibroses after myocardial infarction, cardiac hypertrophy and cardiac insufficiency, arteriosclerosis) and kidney diseases (for example glomerulosclerosis, nephrosclerosis, nephritis, nephropathy,

electrolyte excretion disorder), generally in fibroses and inflammatory processes of any type (for example liver cirrhosis, pulmonary fibrosis, fibrosing pancreatitis, rheumatism and arthroses, Crohn's disease, chronic bronchitis, radiation fibrosis, sclerodermatitis, cystic fibrosis, scarring, Alzheimer's disease).

The compounds according to the invention can also inhibit the growth of tumour cells and tumour metastases and are therefore suitable for tumour therapy.

The compounds according to the invention are also used in the treatment of peptic ulcers, in particular in the case of forms triggered by stress.

The compounds according to the invention are furthermore used for the treatment of coagulopathies, such as, for example, dysfibrinogenaemia, hypoproconvertinaemia, haemophilia B, Stuart-Prower defect, prothrombin complex deficiency, consumption coagulopathy, hyperfibrinolysis, immuno-coagulopathy or complex coagulopathies, and also in neuronal excitability, for example epilepsy. The compounds according to the invention can also be employed therapeutically in the treatment of glaucoma or a cataract.

The compounds according to the invention are furthermore used in the treatment of bacterial infections and in antiinfection therapy. The compounds according to the invention can also be employed therapeutically for increasing learning ability and attention. In addition, the compounds according to the invention counter cell ageing and stress and thus increase life expectancy and fitness in the elderly.

The compounds according to the invention are furthermore used in the treatment of tinnitus.

The identification of small compounds which specifically inhibit, regulate and/or modulate SGK signal transduction is therefore desirable and an aim of the present invention.

It has been found that the compounds according to the invention and salts thereof have very valuable pharmacological properties while being well tolerated.

5 In particular, they exhibit SGK-inhibiting properties.

10 The present invention therefore relates to compounds according to the invention as medicaments and/or medicament active ingredients in the treatment and/or prophylaxis of the said diseases and to the use of compounds according to the invention for the preparation of a pharmaceutical for the treatment and/or prophylaxis of the said diseases and also to a process for the treatment of the said diseases which comprises the administration of one or more compounds according to the invention to a patient  
15 in need of such an administration.

20 The host or patient may belong to any mammal species, for example a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of interest for experimental investigations, where they provide a model for the treatment of a human disease.

25 For identification of a signal transduction pathway and for detection of interactions between various signal transduction pathways, various scientists have developed suitable models or model systems, for example cell culture models (for example Khwaja et al., EMBO, 1997, 16, 2783-93) and models of transgenic animals (for example White et al., Oncogene, 2001,  
30 20, 7064-7072). For the determination of certain stages in the signal transduction cascade, interacting compounds can be utilised in order to modulate the signal (for example Stephens et al., Biochemical J., 2000, 351, 95-105). The compounds according to the invention can also be used as  
35 reagents for testing kinase-dependent signal transduction pathways in animals and/or cell culture models or in the clinical diseases mentioned in this application.

Measurement of the kinase activity is a technique which is well known to the person skilled in the art. Generic test systems for the determination of the kinase activity using substrates, for example histone (for example Alessi et al., FEBS Lett. 1996, 399, 3, pages 333-338) or the basic myelin protein, are described in the literature (for example Campos-González, R. and Glenney, Jr., J.R. 1992, J. Biol. Chem. 267, page 14535).

Various assay systems are available for identification of kinase inhibitors. In the scintillation proximity assay (Sorg et al., J. of Biomolecular Screening, 2002, 7, 11-19) and the flashplate assay, the radioactive phosphorylation of a protein or peptide as substrate is measured using  $\gamma$ ATP. In the presence of an inhibitory compound, a reduced radioactive signal, or none at all, can be detected. Furthermore, homogeneous time-resolved fluorescence resonance energy transfer (HTR-FRET) and fluorescence polarisation (FP) technologies are useful as assay methods (Sills et al., J. of Biomolecular Screening, 2002, 191-214).

Other non-radioactive ELISA assay methods use specific phospho-antibodies (phospho-ABs). The phospho-AB only binds the phosphorylated substrate. This binding can be detected by chemoluminescence using a second peroxidase-conjugated antish sheep antibody (Ross et al., Biochem. J., 2002, 366, 977-981).

#### PRIOR ART

WO 00/62781 describes the use of medicaments comprising inhibitors of cell volume-regulated human kinase H-SGK.

Acylhydrazones are described as SGK inhibitors in WO 2005037773.

Other acylmandelic hydrazides are described as fungicides in

WO 96/17840 and by P. Legrel in *Tetrahedron* **1988**, 44, 4805-4814.

Benzylidenebenzohydrazides having an antibacterial action are described in WO 02/070464 A2. The use of acylhydrazides for the treatment of bacterial infections is disclosed in WO 01/70213.

5 Other acylhydrazone derivatives, inter alia for the treatment of diabetes complications, are disclosed in JP 11-106371.

Methoxy-substituted aromatic acylhydrazone derivatives for the treatment of cancer are described by T. Kametani et al. in Yakugaku Zasshi (1963), 83, 851-855 and in Yakugaku Zasshi (1963), 83, 844-847.

10 Other aromatic acylhydrazone derivatives as sedative enhancers and for lowering blood pressure are disclosed in JP 41-20699.

The use of kinase inhibitors in antiinfection therapy is described by C. Doerig in Cell. Mol. Biol. Lett. Vol.8, No. 2A, 2003, 524-525.

The use of kinase inhibitors in obesity is described by N. Perrotti in J. Biol. Chem. 2001, March 23; 276(12):9406-9412.

20 The following references suggest and/or describe the use of SGK inhibitors in disease treatment:

1: Chung EJ, Sung YK, Farooq M, Kim Y, Im S, Tak WY, Hwang YJ, Kim YI, Han HS, Kim JC, Kim MK. Gene expression profile analysis in human  
25 hepatocellular carcinoma by cDNA microarray. Mol Cells. 2002;14:382-7.

2: Brickley DR, Mikosz CA, Hagan CR, Conzen SD. Ubiquitin modification of serum and glucocorticoid-induced protein kinase-1(SGK-1). J Biol  
30 Chem. 2002;277:43064-70.

3: Fillon S, Klingel K, Warntges S, Sauter M, Gabrysch S, Pestel S, Tanneur V, Waldegger S, Zipfel A, Viebahn R, Haussinger D, Broer S, Kandolf R, Lang F. Expression of the serine/threonine kinase hSGK1 in chronic  
35 viral hepatitis. Cell Physiol Biochem. 2002;12:47-54.

4: Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 2001;21:952-65

5

5: Mikosz CA, Brickley DR, Sharkey MS, Moran TW, Conzen SD. Glucocorticoid receptor-mediated protection from apoptosis is associated with induction of the serine/threonine survival kinase gene, sgk-1. J Biol Chem. 2001;276:16649-54.

10

6: Zuo Z, Urban G, Scammell JG, Dean NM, McLean TK, Aragon I, Honkanen RE. Ser/Thr protein phosphatase type 5 (PP5) is a negative regulator of glucocorticoid receptor-mediated growth arrest. Biochemistry. 1999;38:8849-57.

15

7: Buse P, Tran SH, Luther E, Phu PT, Aponte GW, Firestone GL. Cell cycle and hormonal control of nuclear-cytoplasmic localisation of the serum- and glucocorticoid-inducible protein kinase, Sgk, in mammary tumour cells. A novel convergence point of anti-proliferative and proliferative cell signalling pathways. J Biol Chem. 1999;274:7253-63.

20

8: M. Hertweck, C. Göbel, R. Baumeister: C.elegans SGK-1 is the critical component in the Akt/PKB Kinase complex to control stress response and life span. Developmental Cell, Vol. 6, 577-588, April, 2004.


25

## SUMMARY OF THE INVENTION

30

The invention relates to compounds of the formula I

35



- 10 in which  
 $R^1, R^2$  each, independently of one another, denote H, CHO or acetyl,  
 $R^3, R^4, R^5, R^6, R^7,$   
 $R^8, R^9, R^{10}, R^{11}$  each, independently of one another, denote  
 15 H, A,  $\text{OSO}_2\text{A}$ , Hal,  $\text{NO}_2$ ,  $\text{OR}^{12}$ ,  $\text{N}(\text{R}^{12})_2$ , CN, O-COA,  
 $-\text{[C(R}^{12})_2\text{]}_n\text{COOR}^{12}$ ,  $\text{O-[C(R}^{12})_2\text{]}_o\text{COOR}^{12}$ ,  $\text{SO}_3\text{H}$ ,  
 $-\text{[C(R}^{12})_2\text{]}_n\text{Ar}$ ,  $-\text{CO-Ar}$ ,  $\text{O-[C(R}^{12})_2\text{]}_n\text{Ar}$ ,  $-\text{[C(R}^{12})_2\text{]}_n\text{Het}$ ,  
 $-\text{[C(R}^{12})_2\text{]}_n\text{C}\equiv\text{CH}$ ,  $\text{O-[C(R}^{12})_2\text{]}_n\text{C}\equiv\text{CH}$ ,  $-\text{[C(R}^{12})_2\text{]}_n\text{CON}(\text{R}^{12})_2$ ,  
 $-\text{[C(R}^{12})_2\text{]}_n\text{CONR}^{12}\text{N}(\text{R}^{12})_2$ ,  $\text{O-[C(R}^{12})_2\text{]}_n\text{CON}(\text{R}^{12})_2$ ,  
 20  $\text{O-[C(R}^{12})_2\text{]}_o\text{CONR}^{12}\text{N}(\text{R}^{12})_2$ ,  $\text{NR}^{12}\text{COA}$ ,  $\text{NR}^{12}\text{CON}(\text{R}^{12})_2$ ,  
 $\text{NR}^{12}\text{SO}_2\text{A}$ ,  $\text{N}(\text{SO}_2\text{A})_2$ ,  $\text{COR}^{12}$ ,  $\text{S(O)}_m\text{Ar}$ ,  $\text{SO}_2\text{NR}^{12}$  or  $\text{S(O)}_m\text{A}$ ,  
 $R^3$  and  $R^4$  together also denote  $\text{CH=CH-CH=CH}$ ,  
 $R^3$  and  $R^4, R^7$  and  $R^8$   
 25 or  $R^8$  and  $R^9$  together also denote alkylene having 3, 4 or 5 C atoms,  
 in which one or two  $\text{CH}_2$  groups may be replaced by oxygen,  
 A denotes unbranched or branched alkyl having 1-6 C atoms, in  
 which 1-7 H atoms may be replaced by F,  
 or cyclic alkyl having 3-7 C atoms,  
 30 Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubsti-  
 tuted or mono-, di- or trisubstituted by Hal, A,  $\text{OR}^{12}$ ,  $\text{N}(\text{R}^{12})_2$ ,  
 $\text{NO}_2$ , CN, phenyl,  $\text{CON}(\text{R}^{12})_2$ ,  $\text{NR}^{12}\text{COA}$ ,  $\text{NR}^{12}\text{CON}(\text{R}^{12})_2$ ,  
 $\text{NR}^{12}\text{SO}_2\text{A}$ ,  $\text{COR}^{12}$ ,  $\text{SO}_2\text{N}(\text{R}^{12})_2$ ,  $\text{S(O)}_m\text{A}$ ,  $-\text{[C(R}^{12})_2\text{]}_n\text{-COOR}^{12}$   
 35 and/or  $-\text{O[C(R}^{12})_2\text{]}_o\text{-COOR}^{12}$ ,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be mono-, di- or trisubstituted by Hal, A, OR<sup>12</sup>, N(R<sup>12</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>12</sup>, CON(R<sup>12</sup>)<sub>2</sub>, NR<sup>12</sup>COA, NR<sup>12</sup>SO<sub>2</sub>A, COR<sup>12</sup>, SO<sub>2</sub>NR<sup>12</sup>, S(O)<sub>m</sub>A, =S, =NR<sup>12</sup> and/or =O (carbonyl oxygen),

R<sup>12</sup> denotes H or A,

Hal denotes F, Cl, Br or I,

m denotes 0, 1 or 2,


n denotes 0, 1, 2 or 3,

o denotes 1, 2 or 3,

and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

The invention relates to the compounds of the formula I and salts thereof and to a process for the preparation of compounds of the formula I according to Claims 1-16 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, characterised in that

a) a compound of the formula II




in which

R<sup>1</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup> and R<sup>11</sup> have the meanings indicated in Claim 1,

is reacted with a compound of the formula III

5



III

in which

10


L denotes Cl, Br, I or a free or reactively functionally modified OH group, and  
 R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> have the meanings indicated in Claim 1,

15

or

b) a compound of the formula IV

20



IV

25

in which


R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> have the meanings indicated in Claim 1,

30

is reacted with a compound of the formula V

35

5



V

in which

10

L denotes Cl, Br, I or a free or reactively functionally modified OH group, and  
 $R^1$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  have the meanings indicated in Claim 1,

or

15

- c) a radical  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and/or  $R^{11}$  in a compound of the formula I is converted into another radical  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and/or  $R^{11}$   
 by cleaving an ether by hydrolysis or hydrogenolysis,

20

and/or a base or acid of the formula I is converted into one of its salts.

25

The invention also relates to the stereoisomers (E, Z isomers) and the hydrates and solvates of these compounds. Solvates of the compounds are taken to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alcoholates.

30

Pharmaceutically usable derivatives are taken to mean, for example, the salts of the compounds according to the invention and also so-called pro-drug compounds.

35

Prodrug derivatives are taken to mean compounds of the formula I which have been modified with, for example, alkyl or acyl groups, sugars or

oligopeptides and which are rapidly cleaved in the organism to form the active compounds according to the invention.

These also include biodegradable polymer derivatives of the compounds according to the invention, as is described, for example, in Int. J. Pharm. 115, 61-67 (1995).

The expression "effective amount" means the amount of a medicament or pharmaceutical active ingredient which causes a biological or medical response which is sought or aimed at, for example by a researcher or physician, in a tissue, system, animal or human.

In addition, the expression "therapeutically effective amount" means an amount which, compared with a corresponding subject who has not received this amount, has the following consequence:

improved treatment, healing, prevention or elimination of a disease, syndrome, condition, complaint, disorder or side effects or also the reduction in the progress of a disease, complaint or disorder.

The expression "therapeutically effective amount" also encompasses the amounts which are effective for increasing normal physiological function.

The invention also relates to mixtures of the compounds of the formula I according to the invention, for example mixtures of two diastereomers or enantiomers, for example in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1:100 or 1:1000.

These are particularly preferably mixtures of stereoisomeric compounds, in particular the compounds according to the invention are in the form of the racemate.

For all radicals which occur more than once, their meanings are independent of one another.

Above and below, the radicals and parameters  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  have the meanings indicated for the formula I, unless expressly indicated otherwise.

A denotes alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5 or 6 C atoms. A preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, further preferably, for example, trifluoromethyl.

A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoroethyl.

15

Ac denotes acetyl, Bn denotes benzyl, Ms denotes  $-\text{SO}_2\text{CH}_3$ .

$\text{R}^1$  preferably denotes H, CHO or acetyl, particularly preferably H.

20  $\text{R}^2$  preferably denotes H.

$\text{R}^3$ ,  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$ ,  $\text{R}^8$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$  preferably denote, each independently of one another, H, A, Hal,  $\text{OR}^{12}$  or  $\text{O}-[\text{C}(\text{R}^{12})_2]_n\text{Ar}$ .

$\text{R}^3$  particularly preferably denotes H, A or Hal.

$\text{R}^6$  particularly preferably denotes OH.

25

$\text{R}^8$  particularly preferably denotes OH, A, phenoxy or Hal.

$\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^7$ ,  $\text{R}^9$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$  particularly preferably denote H or A.

$\text{R}^7$ ,  $\text{R}^{10}$ ,  $\text{R}^{11}$  also particularly preferably denote, each independently of one another, H or Hal.

30

$\text{R}^{12}$  particularly preferably denotes H.

35

Ar denotes, for example, phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p-(N-methylamino)phenyl, o-, m- or p-(N-methylaminocarbonyl)phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxy-

phenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p-(N,N-dimethylamino)phenyl, o-, m- or p-(N,N-dimethylaminocarbonyl)-phenyl, o-, m- or p-(N-ethylamino)phenyl, o-, m- or p-(N,N-diethylamino)-phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- or p-(methylsulfonamido)phenyl, o-, m- or p-(methylsulfonyl)phenyl, o-, m- or p-cyanophenyl, o-, m- or p-ureidophenyl, o-, m- or p-formylphenyl, o-, m- or p-acetylphenyl, o-, m- or p-aminosulfonylphenyl, o-, m- or p-carboxyphenyl, o-, m- or p-carboxymethylphenyl, o-, m- or p-carboxymethoxyphenyl, further preferably 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3-nitro-4-chlorophenyl, 3-amino-4-chloro-, 2-amino-3-chloro-, 2-amino-4-chloro-, 2-amino-5-chloro- or 2-amino-6-chlorophenyl, 2-nitro-4-N,N-dimethylamino- or 3-nitro-4-N,N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 2,3,5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromophenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-amino-6-methylphenyl, 3-chloro-4-acetamidophenyl or 2,5-dimethyl-4-chlorophenyl.

Ar preferably denotes, for example, phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR<sup>10</sup>, SO<sub>2</sub>A, COOR<sup>10</sup> or CN, very particularly preferably phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal and/or A, in particular Ar denotes phenyl.

Irrespective of further substitutions, Het denotes, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1-

or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indazolyl, 1-, 3-, 4-, 5-, 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6-quinoxaliny, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, further preferably 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-5-yl.

The heterocyclic radicals may also be partially or fully hydrogenated.

Het can thus also denote, for example, 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or -5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-, -3- or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-, -4- or -5-yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-1-, -2-, -4- or -5-pyrimidinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-, -2-, -3-, -4-, -5-, -6-, -7- or -8-isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8-3,4-dihydro-2H-benzo-1,4-oxazinyl, further preferably 2,3-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4-(difluoromethylenedioxy)phenyl, 2,3-dihydrobenzofuran-5- or -6-yl, 2,3-(2-oxomethylenedioxy)phenyl or also 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7-yl, furthermore preferably 2,3-dihydrobenzofuranyl or 2,3-dihydro-2-oxofuranyl.

Het preferably denotes a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, OH and/or OA.

5 Het particularly preferably denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A.

In a further embodiment, Het very particularly preferably denotes pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl.

10 In a further embodiment, Het particularly preferably denotes furyl, thienyl, pyrrolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, indolyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, Hal, OH and/or OA.

15 The compounds of the formula I may have one or more chiral centres and can therefore occur in various stereoisomeric forms. The formula I encompasses all these forms.

20 Accordingly, the invention relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds may be expressed by the following sub-formulae Ia to Io, which conform to the  
25 formula I and in which the radicals not designated in greater detail have the meaning indicated for the formula I, but in which

in Ia  $R^1$  denotes H or CHO,  
30  $R^2$  denotes H;

in Ib  $R^3, R^4, R^5, R^6, R^7,$   
 $R^8, R^9, R^{10}, R^{11}$  each, independently of one another, denote  
35 H, A, Hal,  $OR^{12}$  or  $O-[C(R^{12})_2]_nAr$ ;

in Ic  $R^6$  denotes OH;

- in Id  $R^3$  denotes H, A or Hal;
- 5 in le  $R^8$  denotes OH, A, phenoxy or Hal;
- in lf  $R^4, R^5, R^7, R^9, R^{10}, R^{11}$  denote H or A;
- 10 in lg  $R^7, R^{10}, R^{11}$  each, independently of one another, denote H or Hal;
- in lh Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal and/or A;
- 15 in li Ar denotes phenyl;
- in lj Het denotes a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, Hal, OH and/or OA;
- 20
- in lk Het denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A;
- 25
- in ll Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, indolyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, Hal, OH and/or OA;
- 30
- 35 in lm  $R^1$  denotes H or CHO,  
 $R^2$  denotes H,

$R^3, R^4, R^5, R^6, R^7,$   
 $R^8, R^9, R^{10}, R^{11}$  each, independently of one another, denote  
 H, A, Hal,  $OR^{12}$  or  $O-[C(R^{12})_2]_nAr$ ;

5

in In

 $R^1$  denotes H or CHO, $R^2$  denotes H, $R^3$  denotes H, A or Hal, $R^4, R^5, R^7, R^9, R^{10}, R^{11}$  denote H or A,

10

 $R^6$  denotes OH, $R^8$  denotes OH, A, phenoxy or Hal;

in Io

15

 $R^1$  denotes H, CHO or acetyl, $R^2$  denotes H, $R^3$  denotes H, A or Hal, $R^4, R^5, R^7,$  $R^{10}, R^{11}$  each, independently of one another, denote H, A

20

or Hal,

 $R^6$  denotes OH, $R^8$  denotes OH, A, phenoxy or Hal, $R^9$  denotes H, Hal or OA, $R^8$  and  $R^9$  together also denote methylenedioxy;




25

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

30

Particular preference is given to the compounds of the formula I selected from the group

35

| No. | Structural formula                                                                                                                                                                            |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5   | <p>"A15"</p>  <p><i>N'</i>-[2-Hydroxy-2-(3-hydroxyphenyl)acetyl]-2-chloro-4,6-dihydroxybenzohydrazide</p>   |
| 10  | <p>"A16"</p>  <p><i>N'</i>-[2-Hydroxy-2-(3-hydroxyphenyl)acetyl]-2-methyl-4,6-dihydroxybenzohydrazide</p> |
| 20  | <p>"A17"</p>  <p><i>N'</i>-[2-Hydroxy-2-(3-hydroxyphenyl)acetyl]-2-ethyl-4,6-dihydroxybenzohydrazide</p>  |
| 30  |                                                                                                                                                                                               |

The compounds according to the invention and also the starting materials for their preparation are, in addition, prepared by methods known per se, as described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic

Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction conditions which are known and suitable for the said reactions. Use may also be made here of variants known per se which are not mentioned here in greater detail.

If desired, the starting materials can also be formed in situ by not isolating them from the reaction mixture, but instead immediately converting them further into the compounds according to the invention.

The starting compounds are generally known. If they are novel, however, they can be prepared by methods known per se.

Compounds of the formula I can preferably be obtained by reacting a hydrazide of the formula II with a compound of the formula III.

The reaction is carried out by methods which are known to the person skilled in the art. The reaction is generally carried out in an inert solvent, optionally in the presence of an acid-binding agent, preferably an organic base, such as DIPEA, triethylamine, dimethylaniline, pyridine or quinoline, or an excess of the carboxyl component of the formula III.

Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro com-

pounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents.

Particularly preferred solvents are water or DMF.

5

The addition of an alkali-metal or alkaline-earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali metals or alkaline-earth metals, preferably of potassium, sodium, calcium or caesium, may also be favourable.

10

Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -30° and 140°, normally between -10° and 90°, in particular between about 0° and about 70°.

15

20

In the compounds of the formula III, L preferably denotes Cl, Br, I or a free or reactively modified OH group, such as, for example, an activated ester, an imidazolidine or alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy or trifluoromethylsulfonyloxy) or arylsulfonyloxy having 6-10 C atoms (preferably phenyl- or p-tolylsulfonyloxy).

25

Radicals of this type for activation of the carboxyl group in typical acylation reactions are described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart).

Activated esters are advantageously formed in situ, for example by addition of HOBt or N-hydroxysuccinimide.

30

Compounds of the formula I can furthermore preferably be obtained by reacting a hydrazide of the formula IV with a compound of the formula V.

35

The reaction is generally carried out in an inert solvent, in the presence of an acid-binding agent, preferably an organic base, such as DIPEA,

triethylamine, dimethylaniline, pyridine or quinoline, or an excess of the carboxyl component of the formula V.

5 Examples of suitable inert solvents are hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloro-  
10 form or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl  
15 ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); carbon  
disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of the said solvents.

20 The addition of an alkali-metal or alkaline-earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali metals or alkaline-earth metals, preferably of potassium, sodium, calcium or caesium, may also be favourable.

25 Depending on the conditions used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about -30° and 140°, normally between -10° and 90°, in particular between about 0° and about 70°.

30 In the compounds of the formula V, L preferably denotes Cl, Br, I or a free or reactively modified OH group, such as, for example, an activated ester, an imidazolidine or alkylsulfonyloxy having 1-6 C atoms (preferably methylsulfonyloxy or trifluoromethylsulfonyloxy) or arylsulfonyloxy having 6-10 C  
35 atoms (preferably phenyl- or p-tolylsulfonyloxy).

Radicals of this type for activation of the carboxyl group in typical acylation reactions are described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart).

5

Activated esters are advantageously formed in situ, for example by addition of HOBt or N-hydroxysuccinimide.

Compounds of the formula I can furthermore be obtained by converting a radical  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}$  and/or  $R^{11}$  into another radical  $R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}$  and/or  $R^{11}$  by, for example, cleaving an ether by hydrolysis or hydrogenolysis.

10

The cleavage of an ether is carried out by methods as are known to the person skilled in the art.

15

A standard method of ether cleavage, for example of a methyl ether, is the use of boron tribromide.

Hydrogenolytically removable groups, for example the cleavage of a benzyl ether, can be cleaved off, for example, by treatment with hydrogen in the presence of a catalyst (for example a noble-metal catalyst, such as palladium, advantageously on a support, such as carbon). Suitable solvents here are those indicated above, in particular, for example, alcohols, such as methanol or ethanol, or amides, such as DMF. The hydrogenolysis is generally carried out at temperatures between about 0 and 100° and pressures between about 1 and 200 bar, preferably at 20-30° and 1-10 bar.

20

25

Esters can be saponified, for example, using acetic acid or using NaOH or KOH in water, water/THF or water/dioxane, at temperatures between 0 and 100°.

30

### 35 Pharmaceutical salts and other forms

The said compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also encompasses

the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of the compounds of the formula I are for the most part prepared by conventional methods. If the compound of the formula I contains a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline-earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methylglutamine. The aluminium salts of the compounds of the formula I are likewise included. In the case of certain compounds of the formula I, acid-addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid-addition salts of the compounds of the formula I include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso-

butyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmo-  
5 ate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a restriction.

Furthermore, the base salts of the compounds according to the invention include aluminium, ammonium, calcium, copper, iron(III), iron(II), lithium,  
10 magnesium, manganese(III), manganese(II), potassium, sodium and zinc salts, but this is not intended to represent a restriction. Of the above-mentioned salts, preference is given to ammonium; the alkali metal salts sodium and potassium, and the alkaline-earth metal salts calcium and mag-  
15 nesium. Salts of the compounds of the formula I which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion  
20 exchanger resins, for example arginine, betaine, caffeine, chlorprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperi-  
25 dine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris-  
(hydroxymethyl)methylamine (tromethamine), but this is not intended to  
30 represent a restriction.

Compounds of the present invention which contain basic nitrogen-con-  
taining groups can be quaternised using agents such as (C<sub>1</sub>-C<sub>4</sub>)alkyl hal-  
35 ides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(C<sub>1</sub>-C<sub>4</sub>)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (C<sub>10</sub>-C<sub>18</sub>)alkyl halides, for example decyl, dodecyl, lauryl, myristyl

and stearyl chloride, bromide and iodide; and aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-soluble compounds according to the invention can be prepared using such salts.

The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this is not intended to represent a restriction.

The acid-addition salts of basic compounds of the formula I are prepared by bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner. The free base can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner. The free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free base forms thereof.

As mentioned, the pharmaceutically acceptable base-addition salts of the compounds of the formula I are formed with metals or amines, such as alkali metals and alkaline-earth metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.

The base-addition salts of acidic compounds according to the invention are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conven-

5 tional manner. The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof.

10 If a compound according to the invention contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride, but this is not intended to represent a restriction.

20 With regard to that stated above, it can be seen that the expression "pharmaceutically acceptable salt" in the present connection is taken to mean an active ingredient which comprises a compound of the formula I in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active  
25 ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.

30 Compounds of the formula I according to the invention may be chiral owing to their molecular structure and may accordingly occur in various enantiomeric forms. They can therefore exist in racemic or in optically active form.

35 Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to

use the enantiomers. In these cases, the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis.

5

In the case of racemic amines, diastereomers are formed from the mixture by reaction with an optically active resolving agent. Examples of suitable resolving agents are optically active acids, such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitably N-protected amino acids (for example N-benzoylproline or N-benzenesulfonylproline), or the various optically active camphorsulfonic acids. Also advantageous is chromatographic enantiomer resolution with the aid of an optically active resolving agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel). Suitable eluents for this purpose are aqueous or alcoholic solvent mixtures, such as, for example, hexane/isopropanol/ acetonitrile, for example in the ratio 82:15:3.

10

15

20

The invention furthermore relates to the use of the compounds and/or physiologically acceptable salts thereof for the preparation of a medicament (pharmaceutical composition), in particular by non-chemical methods. They can be converted into a suitable dosage form here together with at least one solid, liquid and/or semi-liquid excipient or adjuvant and, if desired, in combination with one or more further active ingredients.

25

30

The invention furthermore relates to medicaments comprising at least one compound according to the invention and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

35

Pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active ingredient. Furthermore, pharmaceutical formulations of this type can be prepared using a process which is generally known in the pharmaceutical art.

Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the active ingredient with the excipient(s) or adjuvant(s).

Pharmaceutical formulations adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by

comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present.

Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar, calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medication after the capsule has been taken.

In addition, if desired or necessary, suitable binders, lubricants and disintegrants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. The disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinylpyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an

absorbent, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to granulation, the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape which are broken up to form granules. The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The compounds according to the invention can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.

Oral liquids, such as, for example, solution, syrups and elixirs, can be prepared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compound. Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersion of the compound in a non-toxic vehicle. Solubilisers and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.

The dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like.

5 The compounds according to the invention and salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposome delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.

10 The compounds according to the invention and the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds can also be coupled to soluble polymers as targeted medicament carriers. Such polymers may encompass  
15 polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidophenol, polyhydroxyethylaspartamidophenol or polyethylene oxide polylysine, substituted by palmitoyl radicals. The compounds may furthermore  
20 be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyranes, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.

25 Pharmaceutical formulations adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient. Thus, for example, the active ingredient can  
30 be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318 (1986).

35 Pharmaceutical compounds adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.

For the treatment of the eye or other external tissue, for example mouth and skin, the formulations are preferably applied as topical ointment or cream. In the case of formulation to give an ointment, the active ingredient can be employed either with a paraffinic or a water-miscible cream base. Alternatively, the active ingredient can be formulated to give a cream with an oil-in-water cream base or a water-in-oil base.

Pharmaceutical formulations adapted for topical application to the eye include eye drops, in which the active ingredient is dissolved or suspended in a suitable carrier, in particular an aqueous solvent.

Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes.

Pharmaceutical formulations adapted for rectal administration can be administered in the form of suppositories or enemas.

Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose. Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil.

Pharmaceutical formulations adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insufflators.

Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

5

Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and  
10 aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners. The formulations can be administered in single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition  
15 of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary.

Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets.

20

It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral administration may comprise fla-  
25 vours.

A therapeutically effective amount of a compound of the present invention depends on a number of factors, including, for example, the age and  
30 weight of the human or animal, the precise condition which requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet. However, an effective amount of a compound according to the invention for the treatment is generally in the range from 0.1 to 100 mg/kg of body  
35 weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day. Thus, the actual amount

per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as an individual dose per day or more usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound according to the invention *per se*. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above.

The invention furthermore relates to medicaments comprising at least one compound according to the invention and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.

The invention also relates to a set (kit) consisting of separate packs of

- (a) an effective amount of a compound according to the invention and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
- (b) an effective amount of a further medicament active ingredient.

The set comprises suitable containers, such as boxes, individual bottles, bags or ampoules. The set may, for example, comprise separate ampoules, each containing an effective amount of a compound according to the invention and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient in dissolved or lyophilised form.

**USE**

5 The present compounds are suitable as pharmaceutical active ingredients for mammals, in particular for humans, in the treatment of SGK-induced diseases.

10 The invention thus relates to the use of compounds according to Claim 1, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role. Preference is given here to SGK.

15 Preference is given to the use of compounds according to Claim 1, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,  
20 for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of SGKs by the compounds according to Claim 1.

25 The present invention encompasses the use of the compounds according to Claim 1 according to the invention and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of diabetes (for example diabetes mellitus, diabetic nephropathy, diabetic neuropathy, diabetic angiopathy and microangiopa-  
30 thy), obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases (for example cardiac fibroses after myocardial infarction, cardiac hypertrophy and cardiac insufficiency, arteriosclerosis) and kidney diseases (for example glomerulosclerosis, nephrosclerosis, nephritis, nephropathy, electrolyte excretion disorder),  
35 generally in fibroses and inflammatory processes of any type (for example liver cirrhosis, pulmonary fibrosis, fibrosing pancreatitis, rheumatism and

arthroses, Crohn's disease, chronic bronchitis, radiation fibrosis, sclerodermatitis, cystic fibrosis, scarring, Alzheimer's disease).

5 The compounds according to the invention can also inhibit the growth of cancer, tumour cells and tumour metastases and are therefore suitable for tumour therapy.

10 The compounds according to the invention are furthermore used for the treatment of coagulopathies, such as, for example, dysfibrinogenaemia, hypoproconvertinaemia, haemophilia B, Stuart-Prower defect, prothrombin complex deficiency, consumption coagulopathy, hyperfibrinolysis, immuno-coagulopathy or complex coagulopathies, and also in neuronal excitability, for example epilepsy. The compounds according to the invention can also be employed therapeutically in the treatment of glaucoma or a cataract.

15 The compounds according to the invention are furthermore used in the treatment of bacterial infections and in antiinfection therapy. The compounds according to the invention can also be employed therapeutically for increasing learning ability and attention.

20 Preference is given to the use of compounds according to Claim 1, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment or prevention of diabetes, obesity, metabolic syndrome  
25 (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type, cancer, tumour cells, tumour metastases, coagulopathies, neuronal excitability, glaucoma, cataract, bacterial infections and in anti-  
30 infection therapy, for increasing learning ability and attention, and for the treatment and prophylaxis of cell ageing and stress.

35 Diabetes is preferably diabetes mellitus, diabetic nephropathy, diabetic neuropathy, diabetic angiopathy and microangiopathy.

Cardiovascular diseases are preferably cardiac fibroses after myocardial infarction, cardiac hypertrophy, cardiac insufficiency and arteriosclerosis.

5 Kidney diseases are preferably glomerulosclerosis, nephrosclerosis, nephritis, nephropathy and electrolyte excretion disorder.

10 Fibroses and inflammatory processes are preferably liver cirrhosis, pulmonary fibrosis, fibrosing pancreatitis, rheumatism and arthroses, Crohn's disease, chronic bronchitis, radiation fibrosis, sclerodermatitis, cystic fibrosis, scarring, Alzheimer's disease.

15

20

25

30

35

## ASSAYS

5 The compounds according to the invention described in the examples were tested in the assays described below and were found to have kinase-inhibitory activity. Further assays are known from the literature and could easily be performed by the person skilled in the art (see, for example, Dhanabal et al., *Cancer Res.* 59:189-197; Xin et al., *J. Biol. Chem.* 274:9116-9121; Sheu et al., *Anticancer Res.* 18:4435-4441; Ausprunk et al., *Dev. Biol.* 38:237-248; Gimbrone et al., *J. Natl. Cancer Inst.* 52:413-427; Nicosia et al., *In Vitro* 18:538- 549).

The inhibition of SGK1 protein kinase can be determined in the filter binding method.



15 Above and below, all temperatures are indicated in °C. In the following examples, "conventional work-up" means: if necessary, water is added, the pH is adjusted, if necessary, to values between 2 and 10, depending on the constitution of the end product, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate and evaporated, and the product is purified by chromatography on silica gel and/or by crystallisation. R<sub>f</sub> values on silica gel; eluent: ethyl acetate/methanol 9:1.

20  
25 Mass spectrometry (MS): EI (electron impact ionisation) M<sup>+</sup>  
FAB (fast atom bombardment) (M+H)<sup>+</sup>  
ESI (electrospray ionisation) (M+H)<sup>+</sup> (unless indicated otherwise)

30


### Example 1

35 The preparation of *N'*-[2-(3,4-difluorophenyl)-2-hydroxyacetyl]-2,4-dihydroxy-6-methylbenzohydrazide ("A1") is carried out analogously to the following scheme:



20

$\text{N}_2\text{H}_5\text{OH}$  is monoacylated using 2,4-dibenzyloxy-6-methylbenzoic acid. Yield: 2,4-dibenzyloxy-6-methylbenzohydrazide (63%); m.p. 136-137°.



30

2,4-Dibenzyloxy-6-methylbenzohydrazide is hydrogenated. Yield: 2,4-dihydroxy-6-methylbenzohydrazide (89%); m.p. 226° (decomposition).



35

1.3 282 mg of 3,4-difluoromandelic acid, 410 mg of 2,4-dihydroxy-6-methylbenzohydrazide, 431 mg of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (WSCD) and 164 mg of 1-hydroxybenzotriazole (HOBt) are stirred in 1.5 ml of DMF for 3 h. The mixture is subjected to conventional work-up and chromatographed on silica gel. The uniform fractions are

combined, evaporated and recrystallised from EtOAc/petroleum ether.

Yield 250 mg of "A1" (46%), m.p. 220°C.

The following compounds are obtained analogously:

| No.  | Structural formula<br>Name                                                                                                                                                      | m.p. [°C] |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| "A2" |  <p><i>N'</i>-[2-hydroxy-2-(3-phenoxyphenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p> | 177-178   |
| "A3" |  <p><i>N'</i>-(2-hydroxy-2-phenylacetyl)-2,4-dihydroxy-6-methylbenzohydrazide</p>           | 188-189   |

5

10




15

20

25

30

35

|      |                                                                                                                                                                                          |        |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| "A4" |  <p><i>N'</i>-[2-hydroxy-2-(3-chlorophenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p>            | 215    |
| "A5" |  <p><i>N'</i>-[2-hydroxy-2-(3-trifluoromethylphenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p> | 226    |
| "A6" |  <p><i>N'</i>-[2-acetoxy-2-(3-chlorophenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p>          | 98-100 |

5

10




15

20

25

30

35

|      |                                                                                                                                                                                              |         |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| "A7" |  <p><i>N'</i>-[2-hydroxy-2-(3-fluorophenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p>                | 215-216 |
| "A8" |  <p><i>N'</i>-[2-hydroxy-2-(3,5-difluorophenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p>          | 215-217 |
| "A9" |  <p><i>N'</i>-[2-hydroxy-2-(2,3,4,5,6-pentafluorophenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p> | 224-225 |

5

10




15





20




25

30

35

|       |                                                                                                                                                                                         |         |
|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| "A10" | <br><i>N'</i> -(2-benzo-1,3-dioxol-5-yl-2-hydroxyacetyl)-2,4-dihydroxy-6-methylbenzohydrazide         | 215-216 |
| "A11" | <br><i>N'</i> -[2-hydroxy-2-(3-hydroxy-4-methoxyphenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide | 126-128 |
| "A12" | <br><i>N'</i> -[2-hydroxy-2-(3-chlorophenyl)acetyl]-2,4-dihydroxy-5-chlorobenzohydrazide            | 221-222 |

|    |       |                                                                                                                                                                                            |         |
|----|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| 5  | "A13" |  <p><i>N'</i>-[2-hydroxy-2-(3-chlorophenyl)acetyl]-3-chloro-2-ethyl-4-hydroxybenzohydrazide</p>          | 164-165 |
| 10 | "A14" |  <p><i>N'</i>-[(<i>R</i>)-2-(3-chlorophenyl)-2-hydroxyacetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p> | 234-235 |
| 20 | "A19" |  <p><i>N'</i>-[2-hydroxy-2-(3-methylphenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p>            | 222-223 |
| 30 | "A20" |  <p><i>N'</i>-[2-hydroxy-2-(3,4-difluorophenyl)acetyl]-2,4-dihydroxy-5-methylbenzohydrazide</p>        | 202-203 |
| 35 |       |                                                                                                                                                                                            |         |


|    |       |                                                                                                                                                                                         |                          |
|----|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| 5  | "A21" |  <p><i>N'</i>-[2-formyloxy-2-(3,4-difluorophenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p>     | 92-93<br>(decomposition) |
| 10 | "A22" |  <p><i>N'</i>-[2-hydroxy-2-(3,4-difluorophenyl)acetyl]-2,4-dihydroxy-6-ethylbenzohydrazide</p>       | 189-191                  |
| 15 |       |                                                                                                                                                                                         |                          |
| 20 | "A23" |  <p><i>N'</i>-[2-hydroxy-2-(3,4-difluorophenyl)acetyl]-4-hydroxy-2-ethyl-3-methylbenzohydrazide</p> | 191                      |
| 25 |       |                                                                                                                                                                                         |                          |

**Example 2**

30

Preparation of *N'*-[2-hydroxy-2-(3-hydroxyphenyl)acetyl]-2-chloro-4,6-dihydroxybenzohydrazide ("A15")

35



10

15

720 mg of *N'*-[2-hydroxy-2-(3-hydroxyphenyl)acetyl]-2-chloro-4,6-dibenzoyloxybenzohydrazide in 20 ml of THF + 0.2 ml of 32% HCl are hydrogenated with the calculated amount of H<sub>2</sub> using 360 mg of Pd/C. The hydrogenation solution is evaporated and chromatographed on silica gel. The uniform fractions are combined, evaporated and recrystallised from EtOAc. Yield 310 mg (65%) of "A15", m.p. 230-231°.

20


The following compounds are obtained analogously:

25

30


| No.   | Structural formula                                                                          | m.p. [°C] |
|-------|---------------------------------------------------------------------------------------------|-----------|
| "A16" | <p><i>N'</i>-[2-hydroxy-2-(3-hydroxyphenyl)acetyl]-2-methyl-4,6-dihydroxybenzohydrazide</p> | 214-215   |

35

|       |                                                                                                                                                                                                            |         |
|-------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| "A17" |  <p data-bbox="598 831 1501 934"><i>N'</i>-[2-hydroxy-2-(3-hydroxyphenyl)acetyl]-2-ethyl-4,6-dihydroxybenzohydrazide</p> | 233-234 |
|       |                                                                                                                                                                                                            |         |

**Example 3**

Preparation of *N'*-(2-hydroxy-2-phenylacetyl)-2-methyl-4,6-dihydroxybenzohydrazide ("A18")



"A18"

1.6 g of 2,4-dihydroxy-6-methylbenzoic acid are refluxed with 4 ml of SOCl<sub>2</sub> until a clear solution forms. The SOCl<sub>2</sub> is stripped off, subsequently evaporated to dryness a further 2 x with CH<sub>2</sub>Cl<sub>2</sub>. The acid chloride is then dissolved in 3 ml of DMF, and 1.14 g of mandelic hydrazide are added. After the mixture has been stirred at room temperature for 2 hours, it is added to H<sub>2</sub>O, extracted with EtOAc, dried and evaporated to a small volume. Yield 1.49 g (50%) of "A18", m.p. 188-189°.


Alternative preparation (Example 4):

1.82 g of 2,4-dihydroxy-6-methylbenzohydrazide are dissolved in 10 ml of DMF. 1.71 g of mandeloyl chloride are slowly added. After the mixture has been stirred at room temperature for 2 hours, it is added to H<sub>2</sub>O, extracted with EtOAc, dried and evaporated to a small volume. Yield 2.16 g (68%) of "A18", m.p. 188-189°.

## Syntheses of precursors

### Example 5

*N'*-[2-hydroxy-2-(3-hydroxyphenyl)acetyl]-2,4-dibenzyloxy-6-methylbenzohydrazide



The substance is prepared analogously to Example 1 from 2,4-dibenzyloxy-6-methylbenzohydrazide and 3-hydroxymandelic acid in a yield of 47%, m.p. 181-182° (from Me<sub>2</sub>COH/Et<sub>2</sub>O).


The following compounds are obtained analogously:

*N'*-[2-hydroxy-2-(3-hydroxyphenyl)acetyl]-2-chloro-4,6-dibenzyloxybenzohydrazide, m.p. 160-162° (from Me<sub>2</sub>COH/Et<sub>2</sub>O), 61% yield and

*N'*-[2-hydroxy-2-(3-hydroxyphenyl)acetyl]-2,4-dibenzyloxy-6-ethylbenzohydrazide, m.p. 205-206° (from Me<sub>2</sub>COH/Et<sub>2</sub>O), 90% yield.

### Example 6

#### 2,4-Bisbenzyloxy-6-ethylbenzaldehyde




1.9 g of dihydroxy-6-ethylbenzaldehyde, 3.48 ml of benzyl chloride and 4.7 g of K<sub>2</sub>CO<sub>3</sub> are stirred in 5.2 ml of DMF at 90° for 2 h. The batch is diluted with EtOAc and washed with water. The organic phase is dried using Na<sub>2</sub>SO<sub>4</sub>, evaporated and chromatographed on silica gel. The uniform fractions are combined and evaporated. The oily residue solidifies on standing after a few days. Treatment with ether/petroleum ether 1:1 gives 3.5 g (88%) of 2,4-bisbenzyloxy-6-ethylbenzaldehyde, which discolours in air.

3-Chloro-2-ethyl-4-hydroxybenzoic acid is benzylated analogously: 3-chloro-2-ethyl-4-benzyloxybenzoic acid is obtained in a yield of 78%, m.p. 208-210°.

### Example 7

#### 2,4-Bisbenzyloxy-6-ethylbenzoic acid



3.3 g of 2,4-bisbenzyloxy-6-ethylbenzaldehyde are dissolved in 63 ml of DMSO. A solution of 7.9 g of NaClO<sub>2</sub> and 7.9 g of NaHCO<sub>3</sub> in 32 ml of water is added slowly with ice-cooling, during which the temperature does not exceed 40°C. The mixture is stirred for a further 2 h, before being diluted with further water and extracted 2x with EtOAc. The combined organic phases are washed with water, dried using Na<sub>2</sub>SO<sub>4</sub>, evaporated, chromatographed on silica gel and crystallised from Me<sub>2</sub>COH: yield 2.21 g (64%) of 2,4-bisbenzyloxy-6-ethylbenzoic acid, m.p. 126-127°.

The following are prepared analogously:  
2,4-bisbenzyloxy-6-chlorobenzoic acid, m.p. 135-136° (35%) and  
3-chloro-2-ethyl-4-hydroxybenzoic acid from 3-chloro-2-ethyl-4-hydroxybenzaldehyde: yield 51%, m.p. 138-139°.

### **Example 8**


2,4-Dibenzyloxy-6-ethylbenzohydrazide

The substance is prepared by the method indicated in Example 1 from 2,4-bisbenzyloxy-6-ethylbenzoic acid and hydrazinium hydroxide: yield 75%, m.p. 140-141°.

An analogous preparation procedure also gives 2,4-dibenzyloxy-6-chlorobenzohydrazide: yield 61%, m.p. 166-167°, and  
4-benzyloxy-3-chloro-2-ethylbenzohydrazide: yield 85%, m.p. 182-184°.

### **Example 9**

2,4-Bisbenzyloxy-6-chlorobenzaldehyde



5

12 g of chloro-3,5-dibenzyloxybenzene are dissolved in 40 ml of DMF.

12 ml of  $\text{POCl}_3$  are slowly added dropwise at  $5-10^\circ$ . The mixture is allowed to react further for 90 min at room temperature, then overnight at  $80^\circ\text{C}$ .

10

The solution is evaporated in a Rotavapor, then added to 200 ml of ice-water. The mixture is extracted 3x with EtOAc, washed with water, dried and evaporated. Silica gel chromatography gives 8.2 g (63%) of 2,4-bis-benzyloxy-6-chlorobenzaldehyde, which crystallises from  $(\text{Me}_2\text{C})_2\text{O}$ , m.p.  $85-86^\circ$ .

15

### Example 10

Acetoxy(3-chlorophenyl)acetic acid

20

1 g of racemic 3-chloromandelic acid is mixed with 2 ml of acetyl chloride. A clear solution forms, which, after 2 h, is evaporated in a Rotavapor and crystallised using  $(\text{Me}_2\text{C})_2\text{O}$ /petroleum ether. Yield 670 mg (55%), m.p.  $118^\circ$ .

25

### Example 11

3-Chloro-2-ethyl-4-hydroxybenzohydrazide

30


The compound is prepared by hydrogenation of 300 mg of 3-chloro-2-ethyl-4-benzyloxybenzohydrazide in 10 ml of MeOH and 145  $\mu\text{l}$  of 32% HCl on Pd/Cu. Yield 165 mg (78%),  $233-235^\circ$  (EtOAc/MeCN).

35

The following is prepared analogously: 5-chloro-2,4-dihydroxybenzohydrazide, yield 84%, m.p. 260°.

### **Example 12**

#### **3-Chloro-2-ethyl-4-hydroxybenzaldehyde**



15 3.4 g of *N*-chlorosuccinimide in 40 ml of  $\text{CHCl}_3$  are added dropwise over a period of 45 min to 4 g of 2-ethyl-4-hydroxybenzaldehyde, dissolved in 80 ml of  $\text{CHCl}_3$  and 1.5 ml of conc. HCl. The mixture is stirred for a further 1 h, washed with water, dried and evaporated.

20 Silica-gel chromatography gives 1 g (20%) of 3-chloro-2-ethyl-4-hydroxybenzaldehyde (m.p. 85°, polar substance on silica gel with ether/petroleum ether 1:1) in addition to 5-chloro-2-ethyl-4-hydroxybenzaldehyde (m.p. 83°, moderate polarity) and 3,5-dichloro-2-ethyl-4-hydroxybenzaldehyde (m.p. 117-118°, nonpolar).

25

The following examples relate to pharmaceutical compositions:

#### **Example A: Injection vials**

30 A solution of 100 g of an active ingredient according to the invention and 5 g of disodium hydrogenphosphate in 3 l of bidistilled water is adjusted to pH 6.5 using 2 N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilised under sterile conditions and sealed under sterile conditions. Each injection vial contains 5 mg of active ingredient.

35

**Example B: Suppositories**

5 A mixture of 20 g of an active ingredient according to the invention with 100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient.

**Example C: Solution**

10 A solution is prepared from 1 g of an active ingredient according to the invention, 9.38 g of  $\text{NaH}_2\text{PO}_4 \cdot 2 \text{H}_2\text{O}$ , 28.48 g of  $\text{Na}_2\text{HPO}_4 \cdot 12 \text{H}_2\text{O}$  and 0.1 g of benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to 1 l and sterilised by irradiation. This solution can be used in the form of eye drops.

15

**Example D: Ointment**

500 mg of an active ingredient according to the invention are mixed with 99.5 g of Vaseline under aseptic conditions.

20

**Example E: Tablets**

A mixture of 1 kg of active ingredient, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed to give tablets in a conventional manner in such a way that each tablet contains 25 10 mg of active ingredient.

**Example F: Dragees**

30 Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.

35

**Example G: Capsules**

2 kg of active ingredient are introduced into hard gelatine capsules in a conventional manner in such a way that each capsule contains 20 mg of the active ingredient.

5

**Example H: Ampoules**

A solution of 1 kg of an active ingredient according to the invention in 60 l of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.

10

15

20


25

30

35

# Patent Claims

## 1. Compounds of the formula I



in which

$R^1, R^2$  each, independently of one another, denote H, CHO or acetyl,

$R^3, R^4, R^5, R^6, R^7,$

$R^8, R^9, R^{10}, R^{11}$  each, independently of one another, denote

H, A,  $\text{OSO}_2\text{A}$ , Hal,  $\text{NO}_2$ ,  $\text{OR}^{12}$ ,  $\text{N}(\text{R}^{12})_2$ , CN, O-COA,

$-\text{[C(R}^{12}\text{)}_2\text{]}_n\text{COOR}^{12}$ ,  $\text{O-[C(R}^{12}\text{)}_2\text{]}_o\text{COOR}^{12}$ ,  $\text{SO}_3\text{H}$ ,

$-\text{[C(R}^{12}\text{)}_2\text{]}_n\text{Ar}$ ,  $-\text{CO-Ar}$ ,  $\text{O-[C(R}^{12}\text{)}_2\text{]}_n\text{Ar}$ ,  $-\text{[C(R}^{12}\text{)}_2\text{]}_n\text{Het}$ ,

$-\text{[C(R}^{12}\text{)}_2\text{]}_n\text{C}\equiv\text{CH}$ ,  $\text{O-[C(R}^{12}\text{)}_2\text{]}_n\text{C}\equiv\text{CH}$ ,  $-\text{[C(R}^{12}\text{)}_2\text{]}_n\text{CON}(\text{R}^{12})_2$ ,

$-\text{[C(R}^{12}\text{)}_2\text{]}_n\text{CONR}^{12}\text{N}(\text{R}^{12})_2$ ,  $\text{O-[C(R}^{12}\text{)}_2\text{]}_n\text{CON}(\text{R}^{12})_2$ ,

$\text{O-[C(R}^{12}\text{)}_2\text{]}_o\text{CONR}^{12}\text{N}(\text{R}^{12})_2$ ,  $\text{NR}^{12}\text{COA}$ ,  $\text{NR}^{12}\text{CON}(\text{R}^{12})_2$ ,

$\text{NR}^{12}\text{SO}_2\text{A}$ ,  $\text{N}(\text{SO}_2\text{A})_2$ ,  $\text{COR}^{12}$ ,  $\text{S(O)}_m\text{Ar}$ ,  $\text{SO}_2\text{NR}^{12}$  or  $\text{S(O)}_m\text{A}$ ,

$R^3$  and  $R^4$  together also denote  $\text{CH}=\text{CH}-\text{CH}=\text{CH}$ ,

$R^3$  and  $R^4$ ,  $R^7$  and  $R^8$

or  $R^8$  and  $R^9$  together also denote alkylene having 3, 4 or 5 C atoms,

in which one or two  $\text{CH}_2$  groups may be replaced by oxygen,

A denotes unbranched or branched alkyl having 1-6 C atoms, in which 1-7 H atoms may be replaced by F,

or cyclic alkyl having 3-7 C atoms,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR<sup>12</sup>, N(R<sup>12</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, phenyl, CON(R<sup>12</sup>)<sub>2</sub>, NR<sup>12</sup>COA, NR<sup>12</sup>CON(R<sup>12</sup>)<sub>2</sub>, NR<sup>12</sup>SO<sub>2</sub>A, COR<sup>12</sup>, SO<sub>2</sub>N(R<sup>12</sup>)<sub>2</sub>, S(O)<sub>m</sub>A, -[C(R<sup>12</sup>)<sub>2</sub>]<sub>n</sub>-COOR<sup>12</sup> and/or -O[C(R<sup>12</sup>)<sub>2</sub>]<sub>o</sub>-COOR<sup>12</sup>,  
 Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be mono-, di- or trisubstituted by Hal, A, OR<sup>12</sup>, N(R<sup>12</sup>)<sub>2</sub>, NO<sub>2</sub>, CN, COOR<sup>12</sup>, CON(R<sup>12</sup>)<sub>2</sub>, NR<sup>12</sup>COA, NR<sup>12</sup>SO<sub>2</sub>A, COR<sup>12</sup>, SO<sub>2</sub>NR<sup>12</sup>, S(O)<sub>m</sub>A, =S, =NR<sup>12</sup> and/or =O (carbonyl oxygen),  
 R<sup>12</sup> denotes H or A,  
 Hal denotes F, Cl, Br or I,  
 m denotes 0, 1 or 2,  
 n denotes 0, 1, 2 or 3,  
 o denotes 1, 2 or 3,  
 and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1 in which  
 R<sup>1</sup> denotes H or CHO,  
 R<sup>2</sup> denotes H,  
 and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 or 2 in which  
 R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>,  
 R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup> each, independently of one another, denote  
 H, A, Hal, OR<sup>12</sup> or O-[C(R<sup>12</sup>)<sub>2</sub>]<sub>n</sub>Ar,  
 and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to one or more of Claims 1-3 in which

$R^6$  denotes OH,  
and pharmaceutically usable derivatives, salts, solvates and stereo-  
isomers thereof, including mixtures thereof in all ratios.

5

5. Compounds according to one or more of Claims 1-4 in which  
 $R^3$  denotes H, A or Hal,  
and pharmaceutically usable derivatives, salts, solvates and stereo-  
isomers thereof, including mixtures thereof in all ratios.

10

6. Compounds according to one or more of Claims 1-5 in which  
 $R^8$  denotes OH, A, phenoxy or Hal,  
and pharmaceutically usable derivatives, salts, solvates and stereo-  
isomers thereof, including mixtures thereof in all ratios.

15

7. Compounds according to one or more of Claims 1-6 in which  
 $R^4, R^5, R^7, R^9, R^{10}, R^{11}$  denote H or A,  
and pharmaceutically usable derivatives, salts, solvates and stereo-  
isomers thereof, including mixtures thereof in all ratios.

20

8. Compounds according to one or more of Claims 1-7 in which  
 $R^7, R^{10}, R^{11}$  each, independently of one another, denote H or Hal,  
and pharmaceutically usable derivatives, salts, solvates and stereo-  
isomers thereof, including mixtures thereof in all ratios.

25

9. Compounds according to one or more of Claims 1-8 in which  
Ar denotes phenyl which is unsubstituted or mono-, di- or trisub-  
stituted by Hal and/or A,  
and pharmaceutically usable derivatives, salts, solvates and stereo-  
isomers thereof, including mixtures thereof in all ratios.

30

10. Compounds according to one or more of Claims 1-9 in which  
Ar denotes phenyl,

35

and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

- 5 11. Compounds according to one or more of Claims 1-10 in which  
Het denotes a monocyclic saturated, unsaturated or aromatic  
heterocycle having 1 to 2 N and/or O atoms, which may be  
unsubstituted or mono-, di- or trisubstituted by A, Hal, OH  
and/or OA,  
10 and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
12. Compounds according to one or more of Claims 1-11 in which  
15 Het denotes a monocyclic saturated heterocycle having 1 to 2 N  
and/or O atoms, which may be unsubstituted or mono- or  
disubstituted by A,  
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.  
20
13. Compounds according to one or more of Claims 1-12 in which  
Het denotes furyl, thienyl, pyrrolyl, imidazolyl, pyridyl, pyrimidinyl,  
25 pyrazolyl, thiazolyl, indolyl, pyrrolidinyl, piperidinyl, morpho-  
linyl or piperazinyl, each of which is unsubstituted or mono-,  
di- or trisubstituted by A, Hal, OH and/or OA,  
and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.  
30
14. Compounds according to one or more of Claims 1-13 in which  
R<sup>1</sup> denotes H or CHO,  
R<sup>2</sup> denotes H,  
35 R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>,  
R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup> each, independently of one another, denote  
H, A, Hal, OR<sup>12</sup> or O-[C(R<sup>12</sup>)<sub>2</sub>]<sub>n</sub>Ar,

and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.



- 5 15. Compounds according to one or more of Claims 1-14 in which
- $R^1$  denotes H or CHO,
- $R^2$  denotes H,
- $R^3$  denotes H, A or Hal,
- 10  $R^4, R^5, R^7, R^9, R^{10}, R^{11}$  denote H or A,
- $R^6$  denotes OH,
- $R^8$  denotes OH, A, phenoxy or Hal,
- and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

- 15 16. Compounds according to one or more of Claims 1-15 in which
- $R^1$  denotes H or CHO,
- $R^2$  denotes H,
- 20  $R^3$  denotes H, A or Hal,
- $R^4, R^5, R^7, R^9, R^{10}, R^{11}$  denote H, A or Hal,
- $R^8$  and  $R^9$  together also denote methylenedioxy,
- $R^6$  denotes OH,
- $R^8$  denotes OH, A, phenoxy or Hal,
- 25 and pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.


17. Compounds according to one or more of Claims 1-16 in which
- 30  $R^1$  denotes H, CHO or acetyl,
- $R^2$  denotes H,
- $R^3$  denotes H, A or Hal,
- $R^4, R^5, R^7,$
- 35  $R^{10}, R^{11}$  each, independently of one another, denote H, A or Hal,
- $R^6$  denotes OH,
- $R^8$  denotes OH, A, phenoxy or Hal,

$R^9$  denotes H, Hal or OA,  
 $R^8$  and  $R^9$  together also denote methylenedioxy,  
 and pharmaceutically usable derivatives, salts, solvates and stereo-  
 isomers thereof, including mixtures thereof in all ratios.

18. Compounds according to Claim 1 selected from the group


| No.  | Structural formula<br>Name                                                                                                                                                          |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| "A1" |  <p><i>N'</i>-[2-(3,4-Difluorophenyl)-2-hydroxyacetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p> |
| "A2" |  <p><i>N'</i>-[2-Hydroxy-2-(3-phenoxyphenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p>    |

"A3"




*N'*-(2-Hydroxy-2-phenylacetyl)-2,4-dihydroxy-6-methylbenzohydrazide

"A4"




*N'*-[2-Hydroxy-2-(3-chlorophenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide

"A5"




*N'*-[2-Hydroxy-2-(3-trifluoromethylphenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide

"A6"




*N'*-[2-Acetoxy-2-(3-chlorophenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide

"A7"




*N'*-[2-Hydroxy-2-(3-fluorophenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide

"A8"




*N'*-[2-Hydroxy-2-(3,5-difluorophenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide

"A9"




*N'*-(2-Hydroxy-2-(2,3,4,5,6-pentafluorophenyl)acetyl)-  
2,4-dihydroxy-6-methylbenzohydrazide

"A10"






*N'*-(2-Benzo-1,3-dioxol-5-yl-2-hydroxyacetyl)-2,4-  
dihydroxy-6-methylbenzohydrazide

"A11"



*N'*-(2-Hydroxy-2-(3-hydroxy-4-methoxyphenyl)acetyl)-  
2,4-dihydroxy-6-methylbenzohydrazide


|              |                                                                                                                                            |
|--------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| <p>"A12"</p> | <div data-bbox="892 439 1470 742"> </div> <p><i>N'</i>-[2-Hydroxy-2-(3-chlorophenyl)acetyl]-2,4-dihydroxy-5-chlorobenzohydrazide</p>       |
| <p>"A13"</p> | <div data-bbox="882 994 1491 1305"> </div> <p><i>N'</i>-[2-Hydroxy-2-(3-chlorophenyl)acetyl]-3-chloro-2-ethyl-4-hydroxybenzohydrazide</p>  |
| <p>"A14"</p> | <div data-bbox="886 1558 1495 1869"> </div> <p><i>N'</i>-[(R)-2-(3-Chlorophenyl)-2-hydroxyacetyl]-2,4-dihydroxy-6-methylbenzohydrazide</p> |
| <p>"A15"</p> | <div data-bbox="777 2033 1606 2270"> </div> <p><i>N'</i>-[2-Hydroxy-2-(3-hydroxyphenyl)acetyl]-2-chloro-4,6-dihydroxybenzohydrazide</p>    |

|    |                                                                                                                                                                                              |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 5  | <p>"A16"</p>  <p><i>N'</i>-[2-Hydroxy-2-(3-hydroxyphenyl)acetyl]-2-methyl-4,6-dihydroxybenzohydrazide</p>  |
| 10 |                                                                                                                                                                                              |
| 15 | <p>"A17"</p>  <p><i>N'</i>-[2-Hydroxy-2-(3-hydroxyphenyl)acetyl]-2-ethyl-4,6-dihydroxybenzohydrazide</p> |
| 20 |                                                                                                                                                                                              |
| 25 | <p>"A18"</p>  <p><i>N'</i>-(2-Hydroxy-2-phenylacetyl)-2-methyl-4,6-dihydroxybenzohydrazide</p>           |

30


35

"A19"




*N'*-[2-Hydroxy-2-(3-methylphenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide

"A20"




*N'*-[2-Hydroxy-2-(3,4-difluorophenyl)acetyl]-2,4-dihydroxy-5-methylbenzohydrazide

"A21"



*N'*-[2-Formyloxy-2-(3,4-difluorophenyl)acetyl]-2,4-dihydroxy-6-methylbenzohydrazide

"A22"



*N'*-[2-Hydroxy-2-(3,4-difluorophenyl)acetyl]-2,4-dihydroxy-6-ethylbenzohydrazide

10

15


- 20

25



35

is reacted with a compound of the formula III



III


in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group, and

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> have the meanings indicated in Claim 1,

or

b) a compound of the formula IV




IV

in which

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> have the meanings indicated in Claim 1,

is reacted with a compound of the formula V



in which

L denotes Cl, Br, I or a free or reactively functionally modified OH group, and  
 10  $R^1$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$  have the meanings indicated in Claim 1,

or

15 c) a radical  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and/or  $R^{11}$  in a compound of the formula I is converted into another radical  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and/or  $R^{11}$

20 by cleaving an ether by hydrolysis or hydrogenolysis,

and/or a base or acid of the formula I is converted into one of its salts.

25 20. Medicaments comprising at least one compound according to Claims 1-18 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

30 21. Use of compounds of the formula I according to Claims 1-18, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of  
 35 a medicament for the treatment or prophylaxis of diseases in which

the inhibition, regulation and/or modulation of kinase signal transduction plays a role.

- 5        22. Use according to Claim 21, where the kinase is SGK.
- 10       23. Use according to Claim 22 of compounds according to Claims 1-18, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of SGKs by the compounds according to Claims 1-18.
- 15       24. Use according to Claim 23 of compounds according to Claims 1-18, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment or prevention of diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertension, cardiovascular diseases and kidney diseases, generally in
- 20       fibroses and inflammatory processes of any type, cancer, tumour cells, tumour metastases, coagulopathies, neuronal excitability, glaucoma, cataract, bacterial infections and in antiinfection therapy, for increasing learning ability and attention, and for the treatment and prophylaxis of cell ageing and stress, and for the treatment of tinnitus.
- 25       25. Use according to Claim 24, where diabetes is diabetes mellitus, diabetic nephropathy, diabetic neuropathy, diabetic angiopathy and
- 30       microangiopathy.
- 35       26. Use according to Claim 25, where cardiovascular diseases are cardiac fibroses after myocardial infarction, cardiac hypertrophy, cardiac insufficiency and arteriosclerosis.

WO 2007/093264

PCT/EP2007/000430

- 71 -

27. Use according to claim 24, where kidney diseases are glomerulosclerosis, nephrosclerosis, nephritis, nephropathy and electrolyte excretion disorder.
28. Use according to Claim 24, where fibroses and inflammatory processes are liver cirrhosis, pulmonary fibrosis, fibrosing pancreatitis, rheumatism and arthroses, Crohn's disease, chronic bronchitis, radiation fibrosis, sclerodermatitis, cystic fibrosis, scarring and Alzheimer's disease.
29. Medicaments comprising at least one compound according to Claims 1-18 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
30. Set (kit) consisting of separate packs of
- (a) an effective amount of a compound according to Claims 1-18 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
  - (b) an effective amount of a further medicament active ingredient.

